Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Smoldering Multiple Myeloma × iberdomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 25 Recurrence 4 Lymphoma, Non-Hodgkin 2 Lymphoma, B-Cell 2 Smoldering Multiple Myeloma 1 Neuroblastoma 1 Neoplasms, Plasma Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 Ganglioneuroblastoma 1

Interventions

Lenalidomide 14 Dexamethasone 12 Calcium Dobesilate 7 daratumumab 5 dexamethasone acetate 3 dexamethasone 21-phosphate 3 carfilzomib 3 auricularum 3 Melphalan 3 Curcumin 3 elotuzumab 2 PVX-410 vaccine 2 Leflunomide 2 Denosumab 2 Cyclophosphamide 2 Bortezomib 2 siltuximab 1 selinexor 1 sargramostim 1 pomalidomide 1 poly ICLC 1 piperine 1 pembrolizumab 1 ixazomib 1 isatuximab 1 ibrutinib 1 iberdomide 1 fludarabine phosphate 1 fludarabine 1 citarinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡